During the corresponding time, Rhythm Pharmaceuticals Inc recorded a revenue increase by 46.91 % year on year, sequentially revenue grew by 18.54 %. While revenue at the Rhythm Pharmaceuticals Inc 's corporate clients
In an exciting announcement, Rhythm Pharmaceuticals has unveiled five impactful presentations at the upcoming European Society for Paediatric Endocrinology (ESPE) 2024, focusing on real-world data and therapeutic advancements related to setmelanotide. The data, particularly spotlighting pediatric patients with acquired or congenital hypothalamic obesity, offers a glimpse into the potential of this treatment and its implications for the company and the broader medical community. New Real-World Data on Pediatric PatientsRhythm Pharmaceuticals is making strides in addressing hypothalamic obesity, a challenging condition often seen in pediatric populations. Notably, results from a French early-access program sho...
In recent news, Rhythm Pharmaceuticals announced that their breakthrough drug IMCIVREE (setmelanotide) has received a positive recommendation from the National Institute for Health and Care Excellence (NICE). This recommendation paves the way for IMCIVREE to be funded and available for use within three months in England and Wales through the National Health Service (NHS) in specialist centers. This article aims to outline the important facts regarding this development and evaluate its potential impact on Rhythm Pharmaceuticals.Facts:1. Positive Recommendation from NICE: NICE, the authoritative body responsible for assessing healthcare interventions in the UK, has given IMCIVREE a positive recommendation. Thi...
At the Pediatric Endocrine Society Annual Meeting, Rhythm Pharmaceuticals unveiled data from their Phase 3 pediatrics trial, demonstrating the potential of setmelanotide in treating obesity in young patients. These findings, which show a significant reduction in BMI, mark a crucial step forward in addressing the unmet medical needs of children living with obesity due to POMC/LEPR deficiency or Bardet-Biedl syndrome (BBS). Additionally, Rhythm Pharmaceuticals remains on track to submit a supplemental New Drug Application (sNDA) to the FDA in the first half of 2024, aiming for a label expansion to include pediatric patients. Furthermore, Rhythm Pharmaceuticals has previously revealed their ongoing studies on R...
In a recent groundbreaking study published in The Lancet Diabetes and Endocrinology, Rhythm Pharmaceuticals announced successful results from a Phase 2 clinical trial involving the use of setmelanotide therapy for the treatment of hypothalamic obesity. The findings demonstrated significant reductions in body mass index (BMI) following 16 weeks and one year of treatment, offering new hope for patients suffering from this rare and complex condition.Study Highlights:The study focused on evaluating the effectiveness of setmelanotide therapy in reducing BMI in patients diagnosed with hypothalamic obesity. Hypothalamic obesity is a condition characterized by abnormal weight gain due to dysfunctions involving the h...
Sources:
Rhythm Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Rhythm Pharmaceuticals Inc’s corporate clients.
For your research, we’ve provided 9 tables on Rhythm Pharmaceuticals Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
184.36 %